Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies

Cell & Gene Therapy Insights 2020; 6(7), 1121–1124

10.18609/cgti.2020.121

Published: 3 September 2020
Foreword
Neil Palmer

Neil Palmer is Senior Strategic Adviser and President Emeritus of PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy that he co-founded in 1996. Prior to PDCI, Neil worked with the Patented Medicine Prices Review Board (PMPRB) where his responsibilities included policy development, overseeing the price review of patented medicines and conducting economic research. Prior to the PMPRB, he worked with the Health Division of Statistics Canada where he was responsible for economic and statistical analysis of health care costs and utilization. After completing his studies at the University of Western Ontario, Neil began his career in Montreal with the research group of the Kellogg Centre for Advanced Studies in Primary Care. He has presented extensively on pharmaceutical pricing and reimbursement issues and is a frequent speaker at conferences in North America and Europe.